---
title: "Building Reliability Into Scale-Up: Targeted Optimization for AAV Production"
description: In this webinar, experts share results from a partnership including strategies to maximize AAV yield and ensure consistent quality across scales.
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

# ![New-ATE-Logo2019 (1)](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019%20(1).png?width=700&name=New-ATE-Logo2019%20(1).png)

# Building Reliability Into Scale-Up:

# Targeted Optimization for AAV Production

|  |
| --- |

## Presenter:

****![09-17-2024-Sartorius-ATE-Youssef-HS-Cropped](https://bpi.bioprocessintl.com/hs-fs/hubfs/09-17-2024-Sartorius-ATE-Youssef-HS-Cropped.png?width=136&height=194&name=09-17-2024-Sartorius-ATE-Youssef-HS-Cropped.png)****

**Ahmed Youssef**

*Senior Manager, Upstream Process Development,*

Ascend Advanced Therapies

 

Ahmed Youssef is a senior manager of upstream process development at Ascend. He leads the team responsible for developing safe and effective gene therapies for partners using AAVs. In this role, he draws on more than 12 years of bioprocessing expertise to take AAV gene therapies from the lab to patients by ensuring they can be produced on a large scale with the best possible quality.

Ahmed has a comprehensive background in process development, scale-up, process transfer, and team leadership. He has worked across molecules (mAbs, AAVs, and hormones), including those already in late-stage clinical trials.

 

****![09-17-2024-Sartorius-ATE-Petrovic-HS-Cropped](https://bpi.bioprocessintl.com/hs-fs/hubfs/09-17-2024-Sartorius-ATE-Petrovic-HS-Cropped.png?width=136&height=194&name=09-17-2024-Sartorius-ATE-Petrovic-HS-Cropped.png)****

**Ivana Petrović Koshmak**

*Head of Upstream Process Development,*

Sartorius

 

Ivana Petrović Koshmak is head of upstream process development at Sartorius BIA Separations in Slovenia, leading a group that optimizes production of AAV, adenovirus, exosomes, and other vectors. Her team supports internal research and development, as well customer projects, by developing and applying cell-based assays. The team also supports qPCR, dPCR, and ddPCR analytics, while striving to apply orthogonal methodologies whenever possible.

Ivana is a molecular biologist with a background in gene therapy, previously working at the International Centre for Genetic Engineering and Biotechnology (ICGEB), located in Trieste, Italy. She holds a master’s degree in applied genetics from the University of Belgrade, Serbia, and gained her doctoral degree in biomedical science and biotechnology from the University of Ferrara, Italy.

## About this event:

#### Date: September 17, 2024

#### Time: 11 am EDT | 8 am PDT | 5 pm CEST

#### Duration: 60 minutes

| Scaling up AAV production presents challenges that impact performance and product quality. In this webinar, experts from Sartorius and Ascend Advanced Therapies will share insights on AAV process optimization and scale-up, including strategies to maximize AAV yield and ensure consistency across scales. Key Takeaways: - Learn how a DOE approach and high quality raw materials can streamline process development. - Explore AAV production scaling from 250 mL to 200 L in geometrically consistent bioreactors. - Evaluate the performance of a dual plasmid versus triple transfection. - Discover how key factors (e.g., mixing, oxygen transfer, & volumes) impact performance. |
| --- |

 

-  

-  

©2015 BioProcess International All Rights reserved